[1]陈 嵘,李淑敏,李旭华,等.软坚散结方调控小鼠HIF-1α 糖酵解分子转导抑制肝肿瘤细胞增殖机制研究[J].陕西中医,2023,(7):839-842,848.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.003]
　CHEN Rong,LI Shumin,LI Xuhua,et al.Mechanism study on Ruanjian Sanjie prescription inhibit proliferation of liver cancer cells through regulating HIF-1α pathway[J].,2023,(7):839-842,848.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.003]
点击复制

软坚散结方调控小鼠HIF-1α 糖酵解分子转导抑制肝肿瘤细胞增殖机制研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年7期
页码:
839-842,848
栏目:
基础研究
出版日期:
2023-07-05

文章信息/Info

Title:
Mechanism study on Ruanjian Sanjie prescription inhibit proliferation of liver cancer cells through regulating HIF-1α pathway
作者:
陈 嵘1; 李淑敏1; 李旭华1; 王 振1; 杨 飞1; 2; 李兰青1; 2; 杨文治2; 万伟萍2; 张志云2; 张荣平1; 石西南1
(1.云南中医药大学,云南 昆明 650500; 2.昆明市中医医院,云南 昆明 650032)
Author(s):
CHEN Rong; LI Shumin; LI Xuhua; WANG Zhen; YANG Fei; LI Lanqing; YANG Wenzhi; WAN Weiping; ZHANG Zhiyun; ZHANG Rongping; SHI Xinan
(Yunnan University of Chinese Medicine,Kunming 650500,China)
关键词:
肝癌;  软坚散结方;  活血祛瘀;  缺氧诱导因子;  糖酵解;  细胞增殖
Keywords:
Liver cancer;  Ruanjian Sanjie prescription;  Huoxue Quyu;  HIF-1α;  Glycolysis;  Cell proliferation
分类号:
R 273
DOI:
DOI:10.3969/j.issn.1000-7369.2023.07.003
文献标志码:
A
摘要:
目的:研究软坚散结方调控小鼠HIF-1α糖酵解分子通路抑制肝肿瘤细胞增殖作用。方法:肝癌移植瘤模型小鼠经软坚散结方治疗后,进行瘤组织mRNA筛查,比较组间基因表达及蛋白分子功能差异。结果:软坚散结方干预肝癌移植瘤模型小鼠后,软坚散结组瘤体明显小于对照组。瘤体组织mRNA筛查发现,软坚散结组HIF-1α表达高于对照组(P<0.05)。瘤体组织TUNEL实验表明,软坚散结组肿瘤细胞凋亡高于对照组,且瘤组织蛋白表达HIF-1α、Akt3、HK2、LDHA、GLUT1蛋白表达均低于对照组,而Cleaved Caspase-3高于对照组,差异有统计学意义(均P<0.05)。结论:软坚散结方通过调控小鼠HIF-1α糖酵解通路HK2、LDHA、 GLUT1等蛋白水平,发挥抑制肝肿瘤细胞增生作用。
Abstract:
Objective:To study Ruanjian Sanjie prescription impacting proliferation of liver cancer cells through regulating HIF-1α pathway in mice.Methods:After treatment with Ruanjian Sanjie prescription,mRNA screening of tumor tissue was performed to compare differences in gene expression and protein molecular function between the two groups.Results:After the intervention of Ruanjian Sanjie prescription in liver cancer transplantation model mice,the tumor size of Ruanjian Sanjie group was significantly smaller than that in the control group.mRNA screening of tumor tissue showed that HIF-1α expression in Ruanjian Sanjie group was higher than that in the control group(P<0.05).TUNEL test of tumor tissue showed that the apoptosis of tumor cells in the Ruanjian Sanjie group was higher than that in the control group,and the expression of HIF-1α,Akt3,HK2,LDHA,GLUT1 in tumor tissue lower than those in the control group,while the Cleaved Caspase-3 was higher than that in the control group,difference statistical significance(all P<0.05).Conclusion:Ruanjian Sanjie prescription can inhibit proliferation of hepatocellular carcinoma cells by regulating levels of HK2,LDHA,GLUT1 and other proteins in mouse HIF-1α glycolysis pathway.

参考文献/References:

[1] Jing F,Wang HY.Precision diagnosis and treatment of liver cancer in China[J].Cancer Letters,2018,412(1):283-288.
[2] 陶 琳.原发性肝癌患者化疗后抗菌药物的应用及继发感染的危险因素分析[J].陕西医学杂志,2023,52(1):89-92.
[3] 赵培西,许建秦,袁 彬,等.扶正抗癌方治疗肝癌肝郁脾虚瘀毒证临床研究[J].陕西中医,2022,43(22):1746-1748.
[4] Rauscher S,Greil R,Geisberger R.Re-sensitizing tumor cells to cancer drugs with epigenetic regulators[J].Curr Cancer Drug Targets,2021,21(4):353-359.
[5] Masuda K,Ono A,Chayama K.Erratum to:Serum Hmgb1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy[J].Journal Gastroenterol,2018,53(1):161-162.
[6] Oriana LR,Concetta P,Manlio V.Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of sorafenib in hepatocellular cancer cells[J].Cellular Physiology,2018,233(2):1202-1212.
[7] Li L,Jian L,Xin D.Effects of aidi injection with western medical therapies on quality of life for patients with primary liver cancer:A systematic review and meta-analysis[J].Chin Journal Integr Med,2019,25(10):785-790.
[8] Feng Z,Chun M,Zhang SI,et al.Low dosage of arsenic trioxide inhibits vasculogenic mimicry in hepatoblastoma without cell apoptosis[J].Mol Med Rep,2018,17(1):1573-1582.
[9] Hanahan D,Weinberg RA.Hallmarks of cancer:The next generation[J].Cell,2011,144(5):646-674.
[10] Schwartz L,Supuran CT,Alfarouk KO.The warburg effect and the hallmarks of cancer[J].Anti Cancer Agents Med Chem,2017,17(2):164-170.
[11] Paredes F,Williams HC,San MA.Metabolic adaptation in hypoxia and cancer[J].Cancer Lett,2021,50(2):133-142.
[12] Ganapathy KS.Linking tumor glycolysis and immune evasion in cancer:Emerging concepts and therapeutic opportunities[J].Biochim Biophys Acta Rev Cancer,2017,1868(1):212-220.
[13] Shan W,Zhou Y,Tam KY.The development of small-molecule inhibitors targeting Hexokinase-2[J].Drug Discov Today,2022,27(9):2574-2585.
[14] 梁 婷,斯 韬,刘湘慧,等.糖酵解及其关键限速酶在肝细胞癌中的作用研究进展[J].陕西医学杂志,2022,51(9):1171-1173.
[15] Dewaal D,Nogueira V,Terry Ar,et al.Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin[J].Nat Commun,2018,9(1):446.
[16] Mendez BC,Fondevila F,Garcia PA,et al.Sorafenib resistance in hepatocarcinoma:Role of hypoxia inducible factors[J].Exp Mol Med,2018,50(10):1-9.
[17] Ru XI,Chao WT,Qiu JL,et al.Inhibition of tumor growth and metastasis with antisense oligonucleotides targeting H-tert in an in situ human hepatocellular carcinoma model[J].Acta Pharmacol Sin,2005,26(6):762-768.
[18] Zhong JC,Li XB,Lyu WY,et al.Natural products as potent inhibitors of hypoxia-inducible factor-1α in cancer therapy[J].Chin Journal Nat Med,2020,18(9):696-703.
[19] 钟 崇,黄俊海,陈秋源,等.健脾化瘀法方药对肝肿瘤细胞Smad7蛋白及上皮间质转化的影响[J].中华中医药杂志,2017,32(8):3789-3792.
[20] 王志旭,李 远.中医论治肝癌的医案数据处理转化研究[J].医学研究与教育,2017,34(5):24-29.
[21] 张 振,郜文辉,王亚琪,等.益气化瘀解毒方加减联合索拉非尼治疗原发性肝癌疗效研究[J].陕西中医,2019,40(3):322-324.

相似文献/References:

[1]肖 岚,朱 宏,张 婷,等.董克礼教授治疗原发性肝癌临床经验*[J].陕西中医,2020,(11):1639.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.032]
　XIAO Lan,ZHU Hong,ZHANG Ting,et al.Experience of professor DONG Keli for treating primary liver cancer[J].,2020,(7):1639.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.032]
[2]王 军,徐建良,杜燕红.扶正祛邪汤对肝癌模型大鼠肠道菌群微生态环境的作用研究[J].陕西中医,2021,(2):143.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.002]
　WANG Jun,XU Jianliang,DU Yanhong.Effect of Fuzheng Quxie decoction on intestinal microflora microecological environment of liver cancer model rats[J].,2021,(7):143.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.002]
[3]朱玉辉,柴 劲.黄芪补气汤联合还原型谷胱甘肽对肝癌介入治疗后患者肝功能、氧化应激及炎症的影响[J].陕西中医,2021,(5):570.[doi:DOI:10.3969/j.issn.1000-7369.2020.05.006]
　ZHU Yuhui,CHAI Jin.Effect of Huangqi Buqi decoction combined with reduced glutathione on liver function,oxidative stress and inflammation after interventional therapy for hepatocellular carcinoma[J].,2021,(7):570.[doi:DOI:10.3969/j.issn.1000-7369.2020.05.006]
[4]刘振方,孙巧玉,孟祥彩,等.黄芩素下调微小RNA-130a抑制肝癌细胞侵袭机制研究[J].陕西中医,2021,(12):1667.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.003]
　LIU Zhenfang,SUN Qiaoyu,MENG Xiangcai,et al.Study on mechanism of baicalein down-regulating miR-130a to inhibit hepatocellular carcinoma invasion[J].,2021,(7):1667.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.003]
[5]李武浩,许尤琪.中医药防治肝动脉灌注化疗相关不良反应研究进展[J].陕西中医,2022,(5):673.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.031]
　LI Wuhao,XU Youqi.Clinical research progress of traditional Chinese medicine on the prevention and treatment of related adverse reaction of hepatic artery infusion chemotherapy[J].,2022,(7):673.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.031]
[6]刘 鹏,陈青山,杨建波.柴胡疏肝散加减联合射频消融治疗肝癌疗效研究[J].陕西中医,2023,(7):892.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.015]
　LIU Peng,CHEN Qingshan,YANG Jianbo.Curative effect study on Chaihu Shugan powder combined with radiofrequency ablation for liver cancer[J].,2023,(7):892.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.015]
[7]张宏生,林月洁,陆凤娟.血府逐瘀汤加减联合盐酸吗啡缓释片治疗肝癌疼痛瘀血内阻证疗效研究[J].陕西中医,2023,(7):897.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.016]
　ZHANG Hongsheng,LIN Yuejie,LU Fengjuan.Clinical study on modified Xuefu Zhuyu decoction supplemented with morphine hydrochloride sustained-release tablets in treatment of liver cancer pain of Yuxue Neizu syndrome[J].,2023,(7):897.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.016]
[8]孔庆旭,陈桂云,陈自力,等.槲芪方加减对肝癌化疗栓塞术后大鼠一氧化氮合酶、血管内皮生长因子、乏氧及免疫功能的影响[J].陕西中医,2024,(2):181.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.007]
　KONG Qingxu,CHEN Guiyun,CHEN Zili,et al.Effects of Huqi formula on iNOS,VEGF,hypoxia and immune function of rats after chemoembolization for liver cancer[J].,2024,(7):181.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.007]
[9]郭桓博,马瑞雪,朱正望,等.中药基于铁死亡机制防治肝癌研究进展[J].陕西中医,2024,(2):282.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.030]
　GUO Huanbo,MA Ruixue,ZHU Zhengwang,et al.Research progress in the prevention and treatment of liver cancer based on the mechanism of iron osis in traditional Chinese medicine[J].,2024,(7):282.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.030]
[10]李杳瑶,刘 华,孙铜林,等.鳖甲煎丸对肝癌大鼠黏着斑激酶/雷帕霉素靶蛋白通路的影响[J].陕西中医,2024,(3):308.[doi:DOI:10.3969/j.issn.1000-7369.2024.03.004]
　LI Yaoyao,LIU Hua,SUN Tonglin,et al.Effects of Biejia Jianwan on liver histopathological features and FAK/mTORC1 pathway in rats with hepatocellular carcinoma[J].,2024,(7):308.[doi:DOI:10.3969/j.issn.1000-7369.2024.03.004]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金地区基金资助项目(82060862); 云南省科技厅-云南中医药大学联合项目[202101AZ070001-003/174/250/251,202101AG070-009/029,2019FF002(-050)/(-040),202001AZ070001-066/069]; 云南省科技人才和平台计划项目(202105AG070012); 植物化学与西部植物资源持续利用国家重点实验室开放课题(P2022-KF04)
更新日期/Last Update: 2023-07-10